HCPCS Level II › M
HCPCS Level II codes starting with M
506 codes, page 4 of 6. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| M1297 | Bmi not documented due to medical reason or patient refusal of height or weight measurement | Valid |
| M1298 | Documentation of patient pregnancy anytime during the measurement period prior to and including the current encounter | Valid |
| M1299 | Influenza immunization administered or previously received | Valid |
| M1300 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | Valid |
| M1301 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | Valid |
| M1302 | Screening, diagnostic, film digital or digital breast tomosynthesis (3d) mammography results documented and reviewed | Valid |
| M1303 | Hospice services provided to patient any time during the measurement period | Valid |
| M1304 | Patient did not receive any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period | Valid |
| M1305 | Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period | Valid |
| M1306 | Patient had anaphylaxis due to the pneumococcal vaccine any time during or before the measurement period | Valid |
| M1307 | Documentation stating the patient has received or is currently receiving palliative or hospice care | Valid |
| M1308 | Influenza immunization was not administered, reason not given | Valid |
| M1309 | Palliative care services provided to patient any time during the measurement period | Valid |
| M1310 | Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user | Valid |
| M1311 | Anaphylaxis due to the vaccine on or before the date of the encounter | Valid |
| M1312 | Patient not screened for tobacco use | Valid |
| M1313 | Tobacco screening not performed or tobacco cessation intervention not provided during the measurement period or in the six months prior to the measurement period | Valid |
| M1314 | Bmi not documented and no reason is given | Valid |
| M1315 | Colorectal cancer screening results were not documented and reviewed; reason not otherwise specified | Valid |
| M1316 | Current tobacco non-user | Valid |
| M1317 | Patients who are counseled on connection with a csp and explicitly opt out | Valid |
| M1318 | Patients who did not have documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening or documentation that there was no contact with a csp | Valid |
| M1319 | Patients who had documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening | Valid |
| M1320 | Patients who screened positive for at least 1 of the 5 hrsns | Valid |
| M1321 | Patients who were not seen within 7 weeks following the date of injection for follow up or who did not have a documented iop or no plan of care documented if the iop was >25 mm hg | Valid |
| M1322 | Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop =<25 mm hg for injected eye | Valid |
| M1323 | Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop >25 mm hg and a plan of care was documented | Valid |
| M1324 | Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, or fluocinolone intravitreal implant) | Valid |
| M1325 | Patients who were not seen for reasons documented by clinician for patient or medical reasons (e.g., inadequate time for follow-up, patients who received a prior intravitreal or periocular steroid injection within the last six (6) months and had a subsequent iop evaluation with iop <25mm hg within seven (7) weeks of treatment) | Valid |
| M1326 | Patients with a diagnosis of hypotony | Valid |
| M1327 | Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 8 weeks | Valid |
| M1328 | Patients with a diagnosis of acute vitreous hemorrhage | Valid |
| M1329 | Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 8 weeks after initial acute pvd encounter | Valid |
| M1330 | Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up) | Valid |
| M1331 | Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 8 weeks from initial exam | Valid |
| M1332 | Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 2 weeks | Valid |
| M1333 | Acute vitreous hemorrhage | Valid |
| M1334 | Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 2 weeks after initial acute pvd encounter | Valid |
| M1335 | Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up) | Valid |
| M1336 | Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 2 weeks | Valid |
| M1337 | Acute pvd | Valid |
| M1338 | Patients who had follow-up assessment 30 to 180 days after the index assessment who did not demonstrate positive improvement or maintenance of functioning scores during the performance period | Valid |
| M1339 | Patients who had follow-up assessment 30 to 180 days after the index assessment who demonstrated positive improvement or maintenance of functioning scores during the performance period | Valid |
| M1340 | Index assessment completed using the 12-item whodas 2.0 or sds during the denominator identification period | Valid |
| M1341 | Patients who did not have a follow-up assessment or did not have an assessment within 30 to 180 days after the index assessment during the performance period | Valid |
| M1342 | Patients who died during the performance period | Valid |
| M1343 | Patients who are at pam level 4 at baseline or patients who are flagged with extreme straight line response sets on the pam or with excessive missing responses | Valid |
| M1344 | Patients who did not have a baseline pam score and/or a second score within 4 to 12 months of baseline pam score | Valid |
| M1345 | Patients who had a baseline pam score and a second score within 4 to 12 month of baseline pam score | Valid |
| M1346 | Patients who did not have a net increase in pam score of at least 6 points within a 4 to 12 month period | Valid |
| M1347 | Patients who achieved a net increase in pam score of at least 3 points in a 4 to 12 month period (passing) | Valid |
| M1348 | Patients who achieved a net increase in pam score of at least 6-points in a 4 to 12 month period (excellent) | Valid |
| M1349 | Patients who did not have a net increase in pam score of at least 3 points within a 4 to 12 month period | Valid |
| M1350 | Patients who had a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter | Valid |
| M1351 | Patients who had a suicide safety plan initiated, reviewed, or updated and reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation | Valid |
| M1352 | Suicidal ideation and/or behavior symptoms based on the c-ssrs or equivalent assessment | Valid |
| M1353 | Patients who did not have a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter | Valid |
| M1354 | Patients who did not have a suicide safety plan initiated, reviewed, or updated or reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation | Valid |
| M1355 | Suicide risk based on their clinician's evaluation or a clinician-rated tool | Valid |
| M1356 | Patients who died during the measurement period | Valid |
| M1357 | Patients who had a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment | Valid |
| M1358 | Patients who did not have a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment | Valid |
| M1359 | Index assessment during the denominator period when the suicidal ideation and/or behavior symptoms or increased suicide risk by clinician determination occurs and a non-zero c-ssrs score is obtained | Valid |
| M1360 | Suicidal ideation and/or behavior symptoms based on the c-ssrs | Valid |
| M1361 | Suicide risk based on their clinician's evaluation or a clinician-rated tool | Valid |
| M1362 | Patients who died during the measurement period | Valid |
| M1363 | Patients who did not have a follow-up assessment within 120 days of the index assessment | Valid |
| M1364 | Calculated 10-year ascvd risk score of >= 20 percent during the performance period | Valid |
| M1365 | Patient encounter during the performance period with hospice and palliative care specialty code 17 | Valid |
| M1366 | Focusing on women's health mips value pathway | Valid |
| M1367 | Quality care for the treatment of ear, nose, and throat disorders mips value pathway | Valid |
| M1368 | Prevention and treatment of infectious disorders including hepatitis c and hiv mips value pathway | Valid |
| M1369 | Quality care in mental health and substance use disorders mips value pathway | Valid |
| M1370 | Rehabilitative support for musculoskeletal care mips value pathway | Valid |
| M1371 | Most recent glycemic status assessment (hba1c or gmi) level < 7.0% | Valid |
| M1372 | Most recent glycemic status assessment (hba1c or gmi) level >= 7.0% and < 8.0% | Valid |
| M1373 | Most recent glycemic status assessment (hba1c or gmi) level >= 8.0% and <= 9.0% | Valid |
| M1374 | An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period | Valid |
| M1375 | An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period | Valid |
| M1376 | An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period | Valid |
| M1377 | Recommended follow-up interval for repeat colonoscopy of 10 years documented in colonoscopy report and communicated with patient | Valid |
| M1378 | Documentation of medical reason(s) for not recommending a 10 year follow-up interval (e.g., inadequate prep, familial or personal history of colonic polyps, patient had no adenoma and age is >= 66 years old, or life expectancy < 10 years, other medical reasons) | Valid |
| M1379 | A 10 year follow-up interval for colonoscopy not recommended, reason not otherwise specified | Valid |
| M1380 | Filled at least two prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "denominator note" or the long-acting injectable antipsychotic medications listed under "denominator note" | Valid |
| M1381 | Patients with secondary stroke (e.g., a subsequent stroke that may occur with vasospasm in the setting of subarachnoid hemorrhage) within 5 days of the initial procedure | Valid |
| M1382 | Patient encounter during the performance period with place of service code 11 | Valid |
| M1383 | Acute pvd | Valid |
| M1384 | Patients who died during the performance period | Valid |
| M1385 | Documentation of patient reasons for patients who were not seen for the second pam survey (e.g., less than four months between baseline pam assessment and follow-up | Valid |
| M1386 | Patients with an excisional surgery for melanoma or melanoma in situ in the past 5 years with an initial ajcc staging of 0, i, or ii at the start of the performance period | Valid |
| M1387 | Patients who died during the performance period | Valid |
| M1388 | Patients with documentation of an exam performed for recurrence of melanoma | Valid |
| M1390 | Patients who do not have a documented exam performed for recurrence of melanoma or no documentation within the performance period | Valid |
| M1391 | All patients who were diagnosed with recurrent melanoma during the current performance period | Valid |
| M1392 | Documentation of patient reasons for no examination, i.e., refusal of examination or lost to follow-up (documentation must include information that the clinician was unable to reach the patient by phone, mail or secure electronic mail - at least one method must be documented) | Valid |
| M1393 | Patients who were not diagnosed with recurrent melanoma during the current performance period | Valid |
| M1394 | Stages i-iii breast cancer | Valid |
| M1395 | Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group | Valid |
| M1396 | Patients on a therapeutic clinical trial | Valid |
| M1397 | Patients with recurrence/disease progression | Valid |